← Back to Search

Platelet Aggregation Inhibitor

Temanogrel for Microvascular Obstruction

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (prior to administration of study treatment), anytime between 0 to 15 minutes, 6 hours post-pci and 24 hours post-pci/discharge
Awards & highlights

Study Summary

This study is evaluating whether a drug called temanogrel can improve blood flow in people with heart disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (prior to administration of study treatment) and anytime between 0 to 15 minutes post-pci on day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (prior to administration of study treatment) and anytime between 0 to 15 minutes post-pci on day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Index of Microcirculatory Resistance (IMR) From Baseline to Post Percutaneous Coronary Intervention (PCI)
Secondary outcome measures
Change From Baseline to Post-PCI for Cardiac Troponin I
Change From Baseline to Post-PCI for Coronary Flow Reserve (CFR)
Change From Baseline to Post-PCI for Corrected Thrombolysis in Myocardial Infarction Frame Count (cTFC)
+12 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Stage A (Dose Cohort 2) and Stage B (Dose Group 2)Experimental Treatment1 Intervention
Group II: Stage A (Dose Cohort 1) and Stage B (Dose Group 1)Experimental Treatment1 Intervention
Group III: Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)Placebo Group1 Intervention

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,570 Previous Clinical Trials
10,915,997 Total Patients Enrolled
Arena is a wholly owned subsidiary of PfizerIndustry Sponsor
10 Previous Clinical Trials
2,616 Total Patients Enrolled
Arena PharmaceuticalsLead Sponsor
28 Previous Clinical Trials
5,847 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention
2021. "A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04848220.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top